FDA Approves Durvalumab for Bladder Cancer

May 1, 2017 – The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. A complementary diagnostic for PD-L1, the VENTANA PD-L1 (SP263) … (leggi tutto)